Open AccessThe IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype
Author(s) -
Antonio RiveroJuárez,
Luis F. LópezCortés,
Ángela Camacho,
Antonio Caruz,
Almudena Torres-Cornejo,
Loreto Martínez-Dueñas,
Rosa Ruiz-Valderas,
Julián TorreCisneros,
Alicia GutiérrezValencia,
Antonio Rivero
Publication year - 2013
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328360ea1e
Subject(s) - ribavirin , hepatitis c virus , medicine , pegylated interferon , hepatitis c , virology , viral load , gastroenterology , hepacivirus , genotype , alpha interferon , virus , immunology , interferon , biology , biochemistry , gene
To evaluate the IL28B effect on hepatitis C virus (HCV) decline during first weeks of treatment according to HCV-1 subtypes.